UNH Stock Jumps on Institutional Backing and Vaccine Trial Success
UnitedHealth Group Inc's (NYSE:UNH) stock is on the rise, driven by fresh institutional backing and momentum from recent trial results. The company has seen a significant boost in investor demand, with Patient Capital Management initiating a $181.9 million stake in UNH, making it their fourth-largest holding at around 6% of its total portfolio.
The positive sentiment is also being fueled by the broader healthcare complex's rotation into defensive sectors, following Moderna and Merck's positive Phase 3 trial results for their personalized mRNA cancer vaccine. This uptrend has been further supported by UNH's upcoming $2.32 per share quarterly dividend, set to be distributed on September 22.
In its second-quarter financial results, UnitedHealth Group posted adjusted EPS of $6.38, crushing Wall Street consensus estimates by nearly 30% on revenue of $112.03 billion. CEO Stephen Hemsley emphasized the role of operational streamlining and AI deployment in driving this success, highlighting the potential for continued growth.